Table 2.

Inflammatory cytokine profile of patients with SRC-RT

pg/mL	Controls (n = 9)	Patients with ITP (n = 5)	Patients with SRC-RT (n = 5)
IL-1a	6.03 ± 4.91	11.86 ± 6.33	2.68 ± 0.00*,†
IL-1b	7.06 ± 7.07	7.62 ± 5.77	0.99 ± 0.53†
IL-1RA	2.72 ± 2.44	3.82 ± 1.45	1.79 ± 1.97
IL-2	0.46 ± 0.24	0.33 ± 1.39	0.30 ± 0.00*
IL-6	1.63 ± 1.83	10.94 ± 2.40‡	0.83 ± 1.07†
IL-8	0.76 ± 0.43	2.28 ± 1.40	0.75 ± 0.38
IL-10	0.62 ± 0.00	2.92 ± 5.23‡	0.62 ± 0.00†
IL-12 p40	28.27 ± 12.53	17.03 ± 8.31	40.18 ± 35.87
IL-12 p70	5.31 ± 4.21	2.49 ± 13.40	0.73 ± 0.00†
IL-15	5.63 ± 2.75	9.63 ± 3.35	4.01 ± 2.04†
IL-18	22.05 ± 10.32	23.75 ± 31.09	28.95 ± 12.39
MCP-1	133.42 ± 46.72	200.14 ± 59.40‡	119.00 ± 13.14†
M-CSF	46.45 ± 42.76	137.87 ± 152.15‡	51.27 ± 27.98†
TNF-α	48.85 ± 36.95	49.65 ± 12.83	15.57 ± 6.79*,†

Inflammatory cytokines were assessed in plasma from patients with SRC-RT (n = 5; patients 3, 6, 7, 9, and 11), patients with ITP (n = 5), and healthy controls (n = 9) by using Luminex technology. All results express mean ± standard deviation.

MCP-1, monocyte chemoattractant protein-1; TNF-α, tumor necrosis factor-α.

^*P ≤ .05 for patients with SRC-RT vs controls.

^†P ≤ .05 for patients with SRC-RT vs those with ITP.

^‡P ≤ .05 for patients with ITP vs controls.